Surgery Partners (SGRY) EBITDA Margin (2014 - 2026)
Surgery Partners' (SGRY) quarterly EBITDA Margin came in at 12.03% in Q2 2026, down 149.0% year-over-year from 24.55% in Q2 2025, and up 48.22% quarter-over-quarter from 8.11% in Q1 2026.
Powered by 
Analysis
Surgery Partners (SGRY) EBITDA Margin (2014 - 2026) Analysis & Trends
Surgery Partners has disclosed EBITDA Margin across 13 years of filings, most recently posting 12.03% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 149.0% year-over-year to 12.03%; the TTM figure through Jun 2026 stood at 11.4% (up 23.0% YoY), while the FY2025 annual figure was 16.92%, up 107.0% from the prior year.
- EBITDA Margin came in at 12.03% for Q2 2026 at Surgery Partners, up from 8.11% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 16.84% in Q1 2022 to a low of 6.96% in Q1 2023.
- Average EBITDA Margin over 5 years is 11.86%, with a median of 12.34% recorded in 2022.
- Year-over-year, EBITDA Margin plunged 988 bps in 2023 and surged 496 bps in 2025.
- Over 5 years, EBITDA Margin stood at 13.32% in 2022, then climbed by 4 bps to 13.79% in 2023, then advanced by 7 bps to 14.7% in 2024, then fell by 15 bps to 12.45% in 2025, then retreated by 3 bps to 12.03% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 12.03% in Q2 2026, 8.11% in Q1 2026, and 12.45% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Davita | 11.76 Bn | 12.64 Bn | 1.16 Bn | 16.29% |
| 2 | RadNet | 5.80 Bn | 5.37 Bn | 88.08 Mn | 6.34% |
| 3 | Concentra Group Holdings Parent | 4.40 Bn | 4.26 Bn | 192.10 Mn | 18.99% |
| 4 | Privia Health | 2.61 Bn | 2.25 Bn | - | 1.88% |
| 5 | Pediatrix Medical | 2.20 Bn | 1.79 Bn | - | 11.67% |
| 6 | Fresenius Medical Care AG | 2.11 Bn | 1.41 Bn | 1.52 Bn | 9.58% |
| 7 | Progyny | 2.01 Bn | 1.77 Bn | 89.30 Mn | 11.41% |
| 8 | Surgery Partners | 1.87 Bn | 3.08 Bn | 622.10 Mn | 12.03% |
| 9 | U S Physical Therapy | 1.18 Bn | 1.47 Bn | 41.94 Mn | 10.25% |
| 10 | Starling Oncology | 595.78 Mn | 554.69 Mn | 27.17 Mn | -2.17% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.03% |
| Mar 31, 2026 | 8.11% |
| Dec 31, 2025 | 12.45% |
| Sep 30, 2025 | 12.87% |
| Jun 30, 2025 | 13.52% |
| Mar 31, 2025 | 7.98% |
| Dec 31, 2024 | 14.70% |
| Sep 30, 2024 | 7.90% |
| Jun 30, 2024 | 11.13% |
| Mar 31, 2024 | 10.59% |
| Dec 31, 2023 | 13.79% |
| Sep 30, 2023 | 12.25% |
| Jun 30, 2023 | 14.62% |
| Mar 31, 2023 | 6.96% |
| Dec 31, 2022 | 13.32% |
| Sep 30, 2022 | 11.94% |
| Jun 30, 2022 | 12.43% |
| Mar 31, 2022 | 16.84% |
| Dec 31, 2021 | 18.81% |
| Sep 30, 2021 | 11.37% |